Rituxan: Don't count it out as multiple sclerosis treatment
Posted: Tue Oct 13, 2015 5:54 am
Numerous presentations at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) meeting made it plain that the anti-CD20 biologic drug ocrelizumab may not have the field to itself, if and when it is approved for marketing... Read more - http://www.ms-uk.org/MSnews